Clinical trial · Interventional
Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT
Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing Hematopoietic Stem Cell Transplantation
NCT03320915CI-TRIAL-00030050unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Graft-versus-host-disease (GVHD) is common complication of hematopoietic stem cell transplantation. Vitamin D deficiency has been shown to be associated with increased risk of chronic GVHD in previous clinical studies. The purpose of this research is to investigate the effect of vitamin D supplementation in patients undergoing hematopoietic stem cell transplantation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Neoplasms | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cholecalciferol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cholecalciferol
- description
- Cholecalciferol 5mg (200,000 IU)
- interventionNames
- Drug: Cholecalciferol
- type
- NO_INTERVENTION
- label
- Usual care
- description
- Usual care
Primary outcomes (1)
- measure
- Chronic GVHD
- timeFrame
- Up to 1 year
- description
- Events will be graded according to IBMTR criteria
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults with ≥ 18 years old * Diagnosed with hematologic maligancies * Planned to undergo allogeneic stem cell transplantation Exclusion Criteria: * Hypercalcemia (ionized serum calcium level \[iCa\] \> 1.3 mmol/L, corrected serum calcium level \> 10.5 mg/dL) * Impaired renal function (Serum creatinine ≥ 2.4 mg/dL) * Not in complete remssion (except for myelodysplastic syndrome and myeloproliferative neoplasm) * Consent withdrawal * Considered inadequate under investigator's discretion
References
Publications (0)
Data not yet available
No reference posted for this study.